他汀类药物与细胞增殖性心血管疾病的关系的研究现状
被引量:5
摘要
作者综述了他汀类药物的作用及其机制 ,重点概述了它与高血压病、动脉粥样硬化和经皮腔内冠状动脉成形术后再狭窄的关系。
出处
《心脏杂志》
CAS
2002年第2期162-164,共3页
Chinese Heart Journal
参考文献11
-
1[1]Negre-aminou P,Vliet AK,Erck M,et al.Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types[J].Biochem Biophys Acta,1997,1345: 259-268.
-
2[2]Jiang J,Roman RJ.Lovastatin prevents development of hypertension in spontaneously hypertensive rats [J].Hypertension,1997,30:968-974.
-
3[3]Laufs U,Marra D,Node K,et al.3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of P27kip1 [J].J Bio Chem,1999,274:21926-21931.
-
4[4]Guijarro C,Blanco-Colio LM,Ortego M,et al.3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture [J].Circ Res,1998,83:490-500.
-
5[5]Kano H,Hayashi T,Sumi D,et al.A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO Synthase mRNA [J].Biochem Biophys Res Commu,1999,259:414-419.
-
6[6]Bellosta S,Via D,Canavesi M,et al.HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages[J].Arterioscle Thromb Vasc Biol,1998,18:1671-1678.
-
7[7]Vrtovsnik F,Couettes,Prie D,et al.Lovastatin inhibition of renal epithelial tubular cell proliferation involves a P21ras activated AP-1-dependent pathway[J].Kidney Int,1997,52:1016-1027.
-
8[8]Narisawa J,Morotomi M,Fukaura Y,et al.Chemoprevention by HMG-CoA reductase inhibitor of N-methyl-N-nitrosoureg induced colon carcinogenesis in F344 Rats[J].Jpn J Cancer Res,1996,87:798-804.
-
9[9]Bellosta S,Bernini F,Ferri N,et al.Direct vascular effects of HMG-CoA reductase inhibitor[J].Atherosclerosis,1998,137:s101-s109.
-
10[10]Corsini A,Pazzucconi F,Arnaboldi L,et al.Direct of Effects of statins on the Vascular Wall [J].J Cardiovasc Pharmacol,1998,31:773-778.
同被引文献40
-
1SU S F,HSIAO C L,CHU C W, et al. Effects of pravastatin on ventricular mass in patients with hyperlipidemia and essential hypertension[J]. Am J Cardiol, 2000,86(5):514-518.
-
2BACHENBERG T C, SHUB C, HAUCK A J, et al. Can anatomical left ventricular mass be estimated reliably by Mmode echocardiography? A clinic pathological study of 93 patients[J]. Echocardiography, 1991,8(1):9-15.
-
3HAMMOND I W, DEVEREUX R B, ALDERMAN M H,et al. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adult[J]. J Am Coil Cardiol, 1998,12(4):996-1004.
-
4OLIVETTI G, CIGOLA E, MAESTRI R, et al. Recent advances in cardiac hypertrophy[J]. Cardiovasc Res, 2000,45(1):68-75.
-
5BELL J P, MOSFER S I, LANG D, et al. Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs[J]3. Am J Physiol Heart Circ Physiol,2001,281(4):H1704-H1710.
-
6SUNG J, OUYANG P, BACHER A C, et al. Peripheral endothelium-dependent flow-mediated vasodilatation is associated with left ventricular mass in older persons with hypertention[J]. Am Heart J, 2002,144(1): 39-44.
-
7KREUZER J, WATSON L, HERDEGEN T, et al. Effects of HMG-CoA reductase inhibition on PDGF and angiotension Ⅱ-mediated transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro[J]. Eur J Med Res, 1999,4(4):135-143.
-
8Franz HM, Reinhard K. Left ventricular hypertrophy: a pressure independent cardiovascular risk factor[J].J Cardiovasc Pharmacol,1993,22(suppl 1): S7-S13.
-
9Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG-CoA reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease[J].Cardiovasc Res,2001,49(2):281-287.
-
10Weber KT. Fibrosis and hypertensive heart disease[J].Curr Opin Cardiol,2000,15(4):264-272.
引证文献5
-
1张平洋,邓又斌,杨好意,毕小军.辛伐他汀对原发性高血压左室重量影响的超声观察[J].临床荟萃,2005,20(11):637-638.
-
2张平洋,邓又斌,杨好意,毕小军,潘敏.左旋精氨酸和维生素C合用对自发性高血压大鼠左室肥厚及血管内皮功能的影响[J].中国临床药理学与治疗学,2005,10(12):1384-1388. 被引量:1
-
3徐子悟,惠佳如,吴细文,邓晓磊,孟蕾.核桃仁预防动脉硬化性心血管疾病的网络药理学分析[J].粮油食品科技,2022,30(6):103-113. 被引量:2
-
4李爱国,赵连友,郑强荪,王斌,于心亚,尚福军,田建伟,王士雯.阿伐他汀对成年大鼠心肌成纤维细胞分泌内皮素-1及一氧化氮合酶/一氧化氮系统活性的影响[J].医学研究生学报,2003,16(10):733-735. 被引量:12
-
5李爱国,赵连友,郑强荪,薛玉生,于心亚,王斌,田建伟,杨学东,尚福军.阿伐他汀对自发性高血压大鼠心肌成纤维细胞增殖及胶原合成的影响[J].高血压杂志,2004,12(1):54-57. 被引量:5
二级引证文献20
-
1梁道业,李醒三.他汀类药物抗心肌肥厚的研究进展[J].中国医学文摘(内科学),2005,26(3):360-363.
-
2招霞,孙海翔,胡娅莉,张宁媛,徐志鹏.ICR小鼠胚胎成纤维细胞的培养及饲养层的制作[J].医学研究生学报,2006,19(1):36-39. 被引量:5
-
3朱萧玲,熊利泽,陈绍洋,王强,朱肖星,陈定章,孟华,马晓涛.川芎嗪对内皮素引起心肌细胞肥大的影响[J].医学研究生学报,2006,19(3):214-216. 被引量:8
-
4汪其存,余晓燕,许克莲.高血压患者278例临床分析[J].安徽医药,2006,10(8):597-598. 被引量:6
-
5金培印,韩勤甫,王淑红,申娟,马业新.辛伐他汀对自发性高血压大鼠左心室肥厚作用及心肌转化生长因子-β1表达影响[J].中国心血管杂志,2006,11(6):408-410. 被引量:1
-
6汪进益,范慧敏,刘中民,丁一,马亮,李杨.大鼠皮肤成纤维细胞MyoD cDNA转染后的形态变化[J].同济大学学报(医学版),2007,28(1):6-9. 被引量:3
-
7张国天,刘宗芳.阿托伐他汀在心肌细胞肥大治疗中的作用[J].国际内科学杂志,2007,34(5):268-270.
-
8武宇洲,崔炜,李淑琴,张雷,鲁静朝,张冀东,都军.阿托伐他汀对醛固酮诱导心脏成纤维细胞内皮素表达的影响[J].第四军医大学学报,2007,28(18):1656-1659. 被引量:2
-
9孙红霞,李红,杨世杰.依那普利拉对新生大鼠心肌成纤维细胞增殖及NOS/NO系统的影响[J].吉林大学学报(医学版),2007,33(6):1018-1021. 被引量:8
-
10何世保,王安才.他汀类药物改善心室重构机制的研究进展[J].国外医学(老年医学分册),2009,30(3):113-117.
-
1刘媛媛.他汀类降脂药的实验与临床研究[J].天津药学,2001,13(4):5-7.
-
2刘利.血管紧张素转换酶抑制剂的临床应用[J].国外医学(内科学分册),1994,21(10):429-431. 被引量:4
-
3硫嘌呤类药物增加恶性淋巴细胞增殖性疾病风险[J].中国处方药,2009(11):60-60.
-
4廖开历.他汀类药物的作用机制及应用研究进展[J].中国当代医药,2012,19(7):15-16. 被引量:22
-
5王新嫣.硝苯地平不良反应2例[J].临床心血管病杂志,2002,18(9):479-479.
-
6谢黎崖,张黎静.他汀类药物的研究进展[J].中华临床医药杂志(北京),2003,4(22):111-113.
-
7黄绍湘.他汀类药物的作用及临床应用[J].医学文选,2003,22(4):561-563. 被引量:1
-
8党书毅.全反式维甲酸防治经皮腔内冠状动脉成形术后再狭窄的研究进展[J].中国心血管杂志,2002,7(2):137-139.
-
9李琦文.HMG-CoA还原酶抑制剂-他汀类药物的作用及机制[J].中国现代药物应用,2014,8(17):228-229. 被引量:9
-
10徐辉,朱翠霞.他汀类药物的作用机理及发展前景[J].泰山卫生,2003,27(6):27-28. 被引量:2